[go: up one dir, main page]

NO973659D0 - Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection - Google Patents

Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection

Info

Publication number
NO973659D0
NO973659D0 NO973659A NO973659A NO973659D0 NO 973659 D0 NO973659 D0 NO 973659D0 NO 973659 A NO973659 A NO 973659A NO 973659 A NO973659 A NO 973659A NO 973659 D0 NO973659 D0 NO 973659D0
Authority
NO
Norway
Prior art keywords
lck
treatment
autoimmune diseases
transplant rejection
specific compounds
Prior art date
Application number
NO973659A
Other languages
Norwegian (no)
Other versions
NO973659L (en
Inventor
Damien J Dunnington
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO973659D0 publication Critical patent/NO973659D0/en
Publication of NO973659L publication Critical patent/NO973659L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO973659A 1995-02-10 1997-08-08 Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection NO973659L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US40022095A 1995-03-07 1995-03-07
US49735795A 1995-06-30 1995-06-30
PCT/US1996/001964 WO1996024343A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Publications (2)

Publication Number Publication Date
NO973659D0 true NO973659D0 (en) 1997-08-08
NO973659L NO973659L (en) 1997-10-08

Family

ID=27409758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973659A NO973659L (en) 1995-02-10 1997-08-08 Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection

Country Status (10)

Country Link
EP (2) EP0809490A4 (en)
JP (2) JPH10513474A (en)
KR (1) KR19980702115A (en)
AU (1) AU4923796A (en)
BR (1) BR9607614A (en)
CA (1) CA2212645A1 (en)
FI (1) FI973259A (en)
HU (1) HUP9802078A3 (en)
NO (1) NO973659L (en)
WO (1) WO1996024343A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
CA2559552A1 (en) 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Also Published As

Publication number Publication date
KR19980702115A (en) 1998-07-15
FI973259A0 (en) 1997-08-07
HUP9802078A3 (en) 1999-04-28
JPH10513474A (en) 1998-12-22
BR9607614A (en) 1998-06-09
EP0809490A4 (en) 1999-10-20
WO1996024343A1 (en) 1996-08-15
JPH10513564A (en) 1998-12-22
CA2212645A1 (en) 1996-08-15
AU4923796A (en) 1996-08-27
EP0809490A1 (en) 1997-12-03
EP0811159A1 (en) 1997-12-10
NO973659L (en) 1997-10-08
FI973259A (en) 1997-10-08
HUP9802078A2 (en) 1998-12-28

Similar Documents

Publication Publication Date Title
NO982172D0 (en) Use of epinastine for the treatment of pain
NO976063D0 (en) Procedure for the treatment of diabetes
NO962179L (en) Process for the preparation of metallocene and its use
DK3695A (en) Process and plant for the treatment of biological fluids
DE69630479D1 (en) Medicines for the treatment of inflammatory heart disease
DE69412552D1 (en) Medical instrument for the treatment of sinusitis
FI964874A (en) Treatment of vegetables
NO894296D0 (en) PROCEDURE FOR THE TREATMENT OF ARTHY AND INFLAMMATORY DISEASES.
DE69612465D1 (en) Use of rifamycin derivatives for the treatment of Chlamydia infections
NO920780D0 (en) PROCEDURE AND DEVICE FOR TREATMENT OF EPILEPSY
DE69434492D1 (en) PHOSPHODIESTERASE OF THE HUMAN BRAIN
NO991459D0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
NO955258D0 (en) Medical use of enzymes
NO307740B1 (en) Process for the preparation of catalysts and their use
EE03437B1 (en) Benzenamides for the treatment of neurodegenerative diseases
NO973659D0 (en) Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection
NO910773L (en) COBLE-BASED KNOWLEDGE AND USE OF THIS.
NO973366D0 (en) Procedure for the treatment of multiple sclerosis
NO982562D0 (en) Composition for the treatment of pain
DE69412178D1 (en) Device for the treatment of layers
DK0670721T3 (en) Drug for the treatment and prevention of bone and joint diseases
NO307080B1 (en) Process for the preparation of catalysts and their use
DE69737088D1 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF FIV INFECTIONS
NO931399D0 (en) USE OF NATURSTEIN